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The research of new biomarkers for Parkinson’s disease is essential for accurate and precocious diagnosis, as 
well as for the discovery of new potential disease mechanisms and drug targets. The main objective of this work 
was to identify metabolic changes that might serve as biomarkers for the diagnosis of this neurodegenerative 
disorder. For this, we profiled the plasma metabolome from mice with neurotoxin-induced Parkinson’s disease 
as well as from patients with familial or sporadic Parkinson’s disease. By using mass spectrometry technology, 
we analyzed the complete metabolome from healthy volunteers compared to patients with idiopathic or familial  
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(carrying the G2019S or R1441G mutations in the LRRK2 gene) Parkinson’s disease, as well as, from mice 
treated with 6-hydroxydopamine to induce Parkinson disease. Both human and murine Parkinson was 
accompanied by an increase in plasma levels of unconjugated bile acids (cholic acid, deoxycholic acid and 
lithocholic acid) and purine base intermediary metabolites, in particular hypoxanthine. The comprehensive 
metabolomic analysis of plasma from Parkinsonian patients underscores the importance of bile acids and 
purine metabolism in the pathophysiology of this disease. Therefore, plasma measurements of certain 
metabolites related to these pathways might contribute to the diagnosis of Parkinson’s Disease. 
INTRODUCTION 
 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disease after Alzheimer’s disease, 
affecting 7-10 million people worldwide. PD results 
from a complex interaction between genetic and 
environmental factors, appearing mostly as idiopathic 
cases, with no identifiable cause. Nevertheless, the 
discovery of several gene mutations associated with 
PD onset point to a genetic origin of the disease [1]. 
Mutations in the PARK8/LRRK2 gene are a common 
monogenic cause of PD. They are frequently found in 
early and late onset disease, in addition to this, familial 
or sporadic cases have been detected [2]. The 
substitution of glycine for serine in exon 41 of the 
protein kinase domain in LRRK2 (G2019S mutation), 
is the most common mutation, as was estimated by the 
international LRRK2 consortium, representing 1% of 
sporadic and 4% of familial PD cases worldwide [3]. 
Also, different substitutions in the conserved GTPase 
domain, in exon 31 of LRRK2 (R1441C, R1441G, and 
R1441H) have been identified as important genetic 
causes of familial PD [4]. 
 
Several therapies have been developed to relieve PD-
related symptoms, improving the patient's quality of life 
[5]. However, there are no efficient therapies available to 
stop this neurodegenerative process, and it is necessary to 
discover the mechanisms that trigger the onset of 
neurodegeneration in order to develop etiological 
therapies [6]. 
 
Metabolomic analysis offers an interesting tool to 
identify biochemical networks linked with the 
pathogenesis of this poorly understood disease [7]. Most 
of metabolomic studies are based on the analysis of 
metabolites in cerebrospinal fluid (CSF) [8] and blood 
samples [9], although there are also some studies that 
have examined other biological samples such as urine 
[10, 11] or feces [12]. By using metabolomics, potential 
biomarkers have been discovered, including the 
biopyrrin, described as a new marker of idiopathic PD, 
after being found increased in the urine of these patients 
[11]. Moreover, dysregulated levels of polyamines, 
glutathione, kynurenine, pyruvate or cholesterol were all 
found in the plasma of PD patients compared to healthy 
individuals [13–18].  
Cholesterol is a critical component of membrane 
bilayers and precursor of all steroid hormones and bile 
acids [19]. It plays key structural and functional roles in 
the general metabolism. Deregulations in cholesterol [9, 
17, 18, 20–22] or in some of its products such as bile 
acids [23–25] have been linked to PD. However, studies 
on the association between serum cholesterol level and 
the risks of neurodegenerative diseases are currently 
under debate. High blood cholesterol, is a well-
established risk factor for coronary disease and stroke 
[26, 27], but its role in PD remains controversial. Blood 
concentrations of cholesterol have been associated with 
a higher prevalence of PD [28, 29], and the use of 
cholesterol-lowering drugs, such as statins, have been 
associated with a decrease of PD [18]. However, 
another study failed to detect a significant association 
between serum cholesterol level and PD risk [30]. 
 
In addition, a correlation between changes in plasma levels 
of uric acid (UA) and the progression of neurodegenerative 
disorders has been described [14, 31]. Most notably, 
decreased UA levels in blood (hypouricemia) were found 
in PD patients [32]. In contrast, high levels of UA in 
blood (hyperuricemia) were shown to lower risks for the 
disease [33–35], and to protect against clinical 
progression in PD [36]. However, the mechanisms of this 
neuroprotective role of UA needs to be investigated 
further, as there are some contradictory studies that have 
shown an association between gout (medical condition 
associated with high levels of blood uric acid) and a 
higher [37] or lower [38] risk of PD. 
 
Here, we report an extensive mass spectrometry 
metabolomic analysis of plasma samples from patients 
with genetic and idiopathic PD and from a mouse model 





Convergent metabolic changes observed in plasma 
from PD patients and a mouse model of PD 
 
We performed mass spectrometric metabolomics of 
plasma from: i, patients with idiopathic PD; ii, PD 
patients with the p.G2019S or p.R1441G mutations of 
the LRRK2 gene (Figure 1A and Supplementary Table 
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1); and iii, from a PD mouse model (Supplementary 
Table 2). These mice were treated with the neurotoxin 
6-OHDA, that triggers a rapid degeneration of midbrain 
dopaminergic neurons in the substantia nigra.  
 
Our data revealed that both PD cases exhibit important 
metabolic changes compared to matched controls, both in 
humans (Figure 1A) and in the mouse model 
(Supplementary Table 2). A deep analysis of the 
metabolites levels showed that PD patients groups 
(idiopathic and familial p.G2019S or p.R1441G) clustered 
together, underscoring that the differences observed in all 
metabolome (Figure 1B) or in specific biological 
pathways are very similar between these groups 
(Supplementary Figure 1A). When splitting the 
correlation analysis into subtypes of metabolites, we 
found that bile acids and purine pathways were 
significantly modulated in all PD patients (R value > 0.86 
in all comparisons) (Figure 1C and Supplementary Figure 
1), drawing our attention to these two pathways. 
Increased level of unconjugated bile acids in PD 
patients’ plasma 
 
Bile acid synthesis takes place in liver and consists in 
the oxidation of cholesterol (Supplementary Figure 2A). 
By analyzing the metabolite level, a decrease in the 
levels of cholesterol in plasma of PD patients (Figure 
2A) (p = 0.006) and an important increase of the 
unconjugated bile acids, cholic acid (CA, p = 0.04) 
(Figure 2B), deoxycholic acid (DCA, p < 0.001) (Figure 
2C) and lithocholic acid (LCA, p = 0.06) (Figure 2D) 
were observed. However, except for the glycine-
conjugated DCA (G-DCA) metabolite, no general 
changes were found for other bile acids conjugated with 
glycine (G) (Figure 2E) or taurine (T) (Figure 2F).  
 
No significant differences in cholesterol plasma levels 
(Figure 3A) were noticed in mice treated with 6-OHDA. 
Conversely, a general increase in unconjugated bile acid 




Figure 1. Heatmap clustered by Euclidean distance of changes in plasma metabolite concentrations depicted as Log2 in the control group 
(healthy), idiopathic and familial (carrying the p.G2019S or p.R1441G mutations in LRRK2 gene) Parkinson’s disease (PD) patients (A) or Log2-
fold change between each PD group respect to control group (B). Correlation matrix of all plasma metabolites changed in PD patients is 
shown by color codes (p values and Pearson’s coefficients of correlation (R)) (C). 
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p = 0.02; DCA, p = 0.14; LCA, p = 0.02) (Figure 3B–
3D), with no significant differences in conjugated bile 
acids (Figure 3E, 3F), consistent with the results 
obtained in human PD. 
 
Additionally, bile acids have been described to boost 
the synthesis and storage of glycogen in the liver, which 
leads to an FXR-dependent decrease in blood glucose 
levels [39]. In our models, both in PD patients (all 
patients, Glucose, p value = 0.035) (Supplementary 
Table 1) and in the murine model (All patients, Glucose, 
p value = 0.048) (Supplementary Table 2), we can 
remark a slight but significant hypoglycemia that could 
be an indirect consequence of the increase of bile acids. 
 
The levels of uric acid and purine metabolic pathways 
are altered in plasma of all patients with PD 
 
UA has been reported as a risk factor in PD [35]. 




Figure 2. Box and whisker plots and graphs with average  ± SEM of fold change (Log2) concentrations of cholesterol (A), CA (B), DCA (C), LCA 
(D), G-conjugated bile acids (E) and T-conjugated bile acids (F) in the control group (healthy), idiopathic and familial (harboring the p.G2019S 
or p.R1441G mutations in LRRK2 gene) Parkinson’s disease (PD) patients. Abbreviations: CA, cholic acid; DCA, deoxycholic acid; G, glycine; 




Figure 3. Box and whisker plots and graphs with average ± SEM of fold change (Log2) concentrations of cholesterol (A), CA (B), DCA (C), LCA 
(D), G-CA (E) and T-CA (F) in PD-mouse model. Abbreviations: 6-OHDA, 6-hydroxydopamine; CA, cholic acid; DCA, deoxycholic acid; G, glycine; 
LCA, lithocholic acid; PD, Parkinson’s disease; T, taurine; Unt, untreated.  
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plasma of PD patients (Figure 4A) (p = 0.13), however, 
this decrease was not spectacular. As UA is the end 
product of the metabolism of exogenous- and 
endogenous-derived purines (Supplementary Figure 
3A), we decided to analyze in depth the rest of the 
metabolites of the purine pathway. Interestingly, the 
hypoxanthine levels in patients with PD are much 
higher than in healthy individuals (Figure 4B) (p < 
0.01), but no major changes in xanthine levels (Figure 
4C) were observed in these patients. In addition, 
analyzing the levels of a precursor of hypoxanthine, we 
can see a decrease in the levels of inosine (Figure 4D)  
(p < 0.001). On the same line, we noticed a very 
significant increase in PD patients in the ratios between 
hypoxanthine and its precursor (hypoxanthine/inosine 
ratio) (Figure 4E) (p < 0.001) or its product 
(hypoxanthine/UA ratio) (Figure 4F) (p < 0.001), 
confirming the accumulation of hypoxanthine. In 
summary, we observed an increase in hypoxanthine 
levels and a decrease in both its product and its precursor, 
suggesting a blockade of this metabolic cascade. 
 
As in the previous section, in order to verify these results, 
we also analyzed the modulation of the purine pathways 
in the murine PD model. Remarkably, an increase in the 
level of hypoxanthine was also observed in the serum of 
mice treated with 6-OHDA (Figure 5A) (p < 0.01) 
similarly to the result obtained in patients. In this model, 
the change in hypoxanthine level was accompanied by an 
increase in xanthine levels as well (Figure 5B) (p < 0.05). 
All these results together point to the robustness of the 




Figure 4. Box and whisker plots and graphs with average ± SEM of fold change (Log2) concentrations of uric acid (A), hypoxanthine (B), 
xanthine (C), inosine (D), hypoxanthine/inosine ratio (E) and hypoxanthine/uric acid ratio (F) in the control group (health), idiopathic and 




Figure 5. Box and whisker plots and graphs with average ± SEM of fold change (Log2) concentrations of hypoxanthine (A), xanthine (B), in 
PD-mouse model. Abbreviations: 6-OHDA, 6-hydroxydopamine; Unt, untreated.  
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DISCUSSION 
 
PD is a progressive disorder caused by degeneration of 
neurons in the substantia nigra, the area of the brain 
that controls movement. The first clinical symptoms of 
the disease appear when 80% of these nerve cells have 
disappeared, reducing the effectiveness of dopaminergic 
neurotransmission in this area [40]. Different theories 
related to environmental toxins, genetic factors, and 
accelerated aging have been discussed as possible 
causes of this disease, but most patients diagnosed with 
PD (around 80-85 percent) have what is called primary 
parkinsonism or idiopathic PD, meaning that the cause 
of the disease is unknown. Only a small percentage of 
patients present a genetic cause of PD origin. Five 
Mendelian genes causing familial PD have been 
identified: PARK1/SNCA, PARK2/PARKN, PARK6/ 
PINK1, PARK7/DJ1, as well as the most prevalent one, 
PARK8/LRRK2 [1, 41]. 
 
Our previous work has shown a basal autophagy 
impairment associated with an changes in intracellular 
protein acetylation levels in both genetic and idiopathic 
PD patients, leading to inefficient cellular responses to 
stress and increased susceptibility of cells to neurotoxins 
[41–43]. Indeed, several among the gene defects that 
cause human PD compromise the capacity of cells to 
destroy damaged mitochondria by autophagy 
(mitophagy), increasing cellular vulnerability to external 
and internal stress. 
 
Extensive studies have been performed applying different 
“omic” technologies and particularly the study of the 
metabolome, the collection of small molecules 
(metabolites) contained in biological samples [7]. When 
performed in a high throughput manner [44], 
metabolomics can be considered as an emerging 
technology to explore PD-related biomarkers. Changes in 
metabolite concentrations have been detected in CSF 
samples from PD patients, as reported for oxidized 
glutathione, 3-hydroxykynurenine or homovanillate [8, 
45–47]. However, the extraction of CSF carries some 
associated risks and is highly invasive [48]. Metabolomic 
studies performed on plasma samples, mainly focusing 
on idiopathic PD patients, identified new potential 
biomarkers in PD such as: polyamines [13], long-chain 
acylcarnitines [13], caffeine [49], tryptophan or bilirubin 
[50], glutathione or purine metabolism [14], cholesterol 
[9], kynurenine [15] or pyruvate [16]. However, in the 
past, only one study has been simultaneously performed 
on plasma from idiopathic and genetic (G2019S LRRK2 
mutation) PD patients. That study described that an 
aberration of the purine pathway in PD would account for 
UA changes [51]. Furthermore, one metabolomic study 
has been carried out in parallel on both humans 
idiopathic PD and mice treated with the Parkinsonian 
toxin MPTP. That study reported convergent changes in 
L-DOPA and DOPAC levels in plasma, as well as an 
increase in DRD3 expression on lymphocytes in human 
and murine PD [52]. In the present study, we explored for 
the first time the general metabolome of plasma from 
idiopathic or familial (G2019S or p.R1441G mutations in 
LRRK2 gene) PD patients and also from a 6-OHDA-
treated mice, providing evidence that bile acids and 
purine metabolic pathways play a role in the pathogenesis 
of PD. 
 
We performed an in-depth analysis of the metabolic 
changes observed in plasma from all PD patients 
(idiopathic, p.G2019S or p.R1441G), observing that the 
subgroup of bile acids-pathways metabolites were 
convergently and significantly modulated in all PD 
patients and in 6-OHDA-treated mice. As previously 
shown [53], a significant decrease in the levels of 
cholesterol in the plasma from PD patients was 
observed. However, these alterations in cholesterol 
concentrations were relatively minor compared to the 
large increase in unconjugated bile acids in plasma from 
PD patients (Supplementary Figure 2B) or mice with 
PD (Supplementary Figure 2C). Considering that; i, 
there is still some uncertainty about the role of 
cholesterol in PD; ii, variations on bile acids occur in a 
murine model of prodromal PD in which mice received 
injections of α-SNCA fibrils [24], as well as in human 
idiopathic PD patients [54]; and iii, alterations of 
unconjugated bile acids in plasma occur in other 
neurodegenerative diseases, such as Alzheimer’s 
disease [55]; these results highlight the importance of 
bile acids as a potential early biomarker of PD.  
 
Bile containing bile acids, cholesterol and other 
organic molecules is secreted by hepatocytes into 
canaliculi, flowing into bile ducts. In the liver, the 
synthesis of bile acids represents the majority of 
cholesterol breakdown of the body and plays a critical 
role in the digestion and absorption of lipids in the 
small intestine. Multiple waste products are removed 
from the organism by their secretion into bile and 
finally discarded in feces [56]. However, bile acids can 
be deconjugated and/or dehydroxylated by the 
intestinal microbiota, return to the liver via the portal 
circulation, where they undergo a new round of 
metabolic modification (such as reconjugation) and 
become detectable in systemic venous plasma [57]. 
The increase of unconjugated bile acids in plasma 
levels that we observed in PD may be explained by an 
increased bacterial degradation of conjugated bile 
acids and/or a less efficient removal of unconjugated 
bile acids from the peripheral circulation. 
Interestingly, recent results suggested a bidirectional 
communication between the gut and the brain [58, 59], 
and PD patients indeed exhibit a high prevalence of 
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small intestinal bacterial overgrowth (SIBO) [60]. 
Therefore, a possible method to understand the 
influence of intestinal dysbiosis on these results would 
be through differential bacteria proportions, by 
performing a thorough analysis of fecal microbiota and 
measuring metabolite levels after the removal of the 
bacterial influence. 
 
Another pathway that is significantly modified in both 
human and murine PD concerns purine metabolism. UA 
is one of the products of purine metabolism and many 
studies have shown a correlation between high levels of 
plasma UA and reduced prevalence of idiopathic PD 
[35], suggesting a protective role for this antioxidant. 
We observed a trend towards lower UA levels in plasma 
from PD patients, and also an important increase in 
hypoxanthine levels, an UA precursor (Supplementary 
Figure 3B). Similarly, significant changes were 
observed in this pathway in the PD mouse model, where 
hypoxanthine and xanthine plasma levels increased 
(Supplementary Figure 3C). The mechanisms leading to 
changes in UA associated to PD are not known, and the 
hypothesis that aberrations in the purine pathway occur 
in PD has to be examined in more detail. In 2009, 
Johansen et al. observed that differences in the UA 
precursors could be responsible, at least in part, for the 
final decrease in UA levels observed in PD patients 
[51]. It is interesting to note that in asymptomatic 
LRRK2 p.G2019S carriers, hypoxanthine levels were 
significantly lower, but changes in UA levels were not 
significant. However, in advanced PD, the 
hypoxanthine levels were not significantly modified, 
and the levels of UA were notably reduced [51]. Thus, 
as the disease progresses, there appears to be a tendency 
to increase the levels of UA precursors when UA level 
decrease. 
 
The strength of this study is the reproducibility of 
similar results in several different PD models: plasma 
from idiopathic, familial (p.G2019S and p.R1441G 
LRRK2) PD patients, and from a 6-OHDA-induced 
mouse model of PD, being the first complete 
metabolomic study carried out with these 
characteristics. The main limitation of our study lies in 
the number of individuals being tested. Increasing the 
number of patients studied would most likely strengthen 
the results. Moreover, it might be interesting to analyze 
asymptomatic LRRK2 mutation carriers to understand 
whether the metabolomic shifts observed here occur 
before the disease becomes clinically apparent. 
 
In summary, the present study identified robust changes 
in bile acids and purine pathways that may constitute 
biomarkers for both idiopathic and familial PD and 
potentially reflect pathogenesis-relevant metabolic 
alterations. 
MATERIALS AND METHODS 
 
PD patients:  
 
Clinically established PD patients according to UK 
Bank criteria and healthy controls were divided into 
four groups (N=8/group): 1) healthy control individuals, 
2) idiopathic PD patients, patients with 3) LRRK2 
p.G2019S mutation, and 4) LRRK2 p.R1441G mutation. 
All the patient information (including age, gender and 
treatment received) is shown in Table 1. No interactions 
between gender or age and metabolic changes were 
observed (Table 2). All PD patients were treated  
with different antiparkinsonian medications (mainly 
levodopa/carbidopa or statins+levodopa/|carbidopa), but 
no significant differences in the metabolic changes 
between the two sub-groups within the PD patients were 
reported (Table 2). After informed consent approved by 
the Ethical Board of Hospital Donostia (ALM-LRRK2-
2016-01) a blood sample was taken from antecubital 
vein after overnight fast and immediately processed to 
separate plasma and cells and stored at -80ºC until 
further experiments.  
 
Mouse strains and housing  
 
All animal experiments were approved by the “Ethics 
Committee for Animal Experimentation” of the 
Biomedical Research Institute “Alberto Sols” (CSIC-
UAM) in Madrid (Spain) and carried out in accordance 
with the European Communities Council Directive 
(2010/63/EEC) and National regulations (normative 
RD1386/2018). Adult, male wild type C57/BL6 mice 
were obtained from Jackson Laboratories. The animals 
were housed in a cage (2–3 animals per cage) with free 
access to food and water under a 12 h light/dark cycle. 
Special care was taken to minimize pain or discomfort 
of animals. 
 
Animal model of PD 
 
Parkinsonism was induced as previously described [61]. 
Briefly, anaesthetized mice were placed in a stereotaxic 
apparatus (Kopf Instruments, CA) and 6-OHDA (5µg in 
2µL saline with 0.02% ascorbic acid) was unilaterally 
injected into the substantia nigra pars compacta at the 
following coordinates from bregma: posterior, -3.2 mm; 
lateral, +2.0 mm; and ventral, +4.7 mm, with the skull 
flat between lambda and bregma, according to the atlas 
of Paxinos and Franklin [62]. Mice were then housed to 
recover. 
 
Plasma sample preparation 
 
A volume of 25 µL of plasma were mixed with 250 µL 
a cold solvent mixture with ISTD (MeOH/
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Table 1. Patient information. 
Sample ID code Age (years, at plasma collection) Gender Health Condition Treatment  
FH17-07 64 Female Healthy individual Untreated 
FH17-08 77 Male Healthy individual Untreated 
FH17-09 68 Female Healthy individual Untreated 
FH17-10 65 Female Healthy individual Untreated 
FH17-11 72 Female Healthy individual Untreated 
FH17-12 72 Female Healthy individual Untreated 
FH17-16 76 Female Healthy individual Untreated 
FH17-18 68 Female Healthy individual Untreated 
FH16-24 77 Male Idiopathic PD patient Statins 
FH16-25 65 Male Idiopathic PD patient Statins + Levodopa 
FH16-26 63 Male Idiopathic PD patient Levodopa 
FH16-31 81 Female Idiopathic PD patient Levodopa 
FH16-32 85 Male Idiopathic PD patient Levodopa 
FH16-34 71 Male Idiopathic PD patient Levodopa 
FH16-35 71 Male Idiopathic PD patient Statins 
FH16-38 48 Male Idiopathic PD patient Levodopa 
FH13-11 84 Female p.G2019S PD patient Levodopa 
FH13-13 73 Female p.G2019S PD patient Levodopa 
FH16-39 81 Male p.G2019S PD patient Levodopa 
FH16-43 77 Female p.G2019S PD patient Statins + Levodopa 
FH16-44 79 Female p.G2019S PD patient Statins + Levodopa 
FH17-03 78 Female p.G2019S PD patient Levodopa 
FH17-01 67 Female p.G2019S PD patient Statins + Levodopa 
FH16-45 73 Female p.G2019S PD patient  Levodopa 
FH16-27 72 Male p.R1441G PD patient  Levodopa 
FH16-28 68 Male p.R1441G PD patient  Levodopa 
FH17-15 67 Male p.R1441G PD patient  Statins + Levodopa 
FH13-11 88 Female p.R1441G PD patient  Statins + Levodopa 
FH13-13 77 Female p.R1441G PD patient  Untreated 
FH09-78 67 Male p.R1441G PD patient  Statins + Levodopa 
FH10-11 54 Male p.R1441G PD patient  Levodopa 
FH10-12  59 Female p.R1441G PD patient  Levodopa 
Abbreviations: PD, Parkinson’s disease. 
 
Water/Chloroform, 9/1/1, -20°C), into 1.5 mL 
microtube, vortexed and centrifuged (10 min at 15000 
g, 4°C) to obtain protein precipitation. Then upper 
phase of supernatant was split in parts: 50 µL were used 
for GC-MS experiment in injection vial, and 50 µL 
were used for other UHPLC-MS experimentations. GC-
MS aliquot was evaporated and 50 µL of methoxyamine 
(20 mg/mL in pyridine) were added on dried extracts, 
then stored at room temperature in dark, during 16 
hours. After that, 80 µL of N-Methyl-N-(trimethylsilyl) 
trifluoroacetamide (MSTFA) was added and final 
derivatization occurred at 40°C during 30 minutes. 
Samples were directly injected into GC-MS. The whole 
was heated at 40°C during 1h. 60 µL of H20 was added 
and the whole was injected into UHPLC-MS. 
Concerning the LC-MS aliquots, the 50 µL collected 
supernatant was evaporated at 40°C in a pneumatically-
assisted concentrator (Techne DB3, Staffordshire, UK). 
The LC-MS dried extracts were solubilized with 150 µL 
of MilliQ water. Samples were aliquoted for LC 
methods and backup. Biological samples and QC 
aliquots are kept at -80°C until injection or transferred 
in vials for direct analysis by UHPLC/MS. All the 
reagents used in this study are, if not specified, from 
Sigma-Aldrich. 
 
Widely-targeted analysis of metabolites gas 
chromatography (GC) coupled to a triple 
quadrupole (QQQ) mass spectrometer 
 
GC-MS/MS method was performed on a 7890B gas 
chromatography coupled to a triple quadrupole 7000C 
(Agilent Technologies, Waldbronn, Germany) equipped 
with a High sensitivity electronic impact source (EI) 
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Table 2. Effects of gender, age and treatment received on the results obtained. 




Mean of PD 
female 
p value 
Mean of PD 
male 
Mean of PD 
female 
p value 
Uric acid -0,0788 -0,8681 * -0,0805 -0,8681 * 
Hypoxanthine 0,2608 1,7860 * 1,6430 1,7860 n.s. 
Inosine 0,1051 -0,5730 ** -0,5820 -0,5730 n.s. 
Xanthine -0,0384 0,4768 n.s. 0,0812 0,4768 n.s. 
Cholesterol 0,0027 -0,2105 * -0,2738 -0,2105 n.s. 
CA -0,2193 2,0500 * 1,7480 2,0500 n.s. 
LCA -0,4863 1,0380 n.s. 1,2440 1,0380 n.s. 
DCA -0,1294 2,4460 ** 2,5520 2,4460 n.s. 
G-CA -0,0499 0,2865 n.s. 0,1431 0,2865 n.s. 
G-DCA -0,1316 2,0740 * 2,1380 2,0740 n.s. 
T-CA -0,0576 -0,4365 n.s. -0,4339 -0,4365 n.s. 
T-DCA -0,1311 0,4159 n.s. 0,9882 0,4159 n.s. 
 
Analysis by age (Correlations between age and metabolic changes) 














p value  
(two-tailed) 
Uric acid 0,0004 n.s. 0,0019 n.s. 0,3176 n.s. 0,0461 n.s. 0,6650 * 
Hypoxanthine 0,0516 n.s. 0,0963 n.s. 0,3447 n.s. 0,1044 n.s. 0,1376 n.s. 
Inosine 0,0000 n.s. 0,0020 n.s. 0,0171 n.s. 0,0003 n.s. 0,0070 n.s. 
Xanthine 0,0148 n.s. 0,0226 n.s. 0,1705 n.s. 0,0184 n.s. 0,0348 n.s. 
Cholesterol 0,0045 n.s. 0,0086 n.s. 0,1640 n.s. 0,0053 n.s. 0,0457 n.s. 
CA 0,0428 n.s. 0,0321 n.s. 0,0459 n.s. 0,2118 n.s. 0,0876 n.s. 
LCA 0,0137 n.s. 0,0218 n.s. 0,1566 n.s. 0,0259 n.s. 0,0010 n.s. 
DCA 0,0305 n.s. 0,0163 n.s. 0,0007 n.s. 0,0036 n.s. 0,1576 n.s. 
G-CA 0,0289 n.s. 0,0220 n.s. 0,0231 n.s. 0,0291 n.s. 0,0920 n.s. 
G-DCA 0,0527 n.s. 0,0516 n.s. 0,1204 n.s. 0,1568 n.s. 0,0250 n.s. 
T-CA 0,0004 n.s. 0,0047 n.s. 0,0002 n.s. 0,0252 n.s. 0,3312 n.s. 
T-DCA 0,0080 n.s. 0,0368 n.s. 0,0852 n.s. 0,0125 n.s. 0,5425 * 
 





Mean of PD 
patients 




Mean of PD 
patients 
(Levodopa+ 
Statins) p value 
Mean of PD 
patients 
(Levodopa) 
Mean of PD 
patients 
(Levodopa+ 
Statins) p value 
Uric acid 0,0962 -0,3709 n.s. 0,0962 -0,1443 n.s. -0,3709 -0,1443 n.s. 
Hypoxanthine 0,2592 1,7140 ** 0,2592 2,3000 ** 1,7140 2,3000 n.s. 
Inosine 0,0368 -0,6213 ** 0,0368 -0,4592 n.s. -0,6213 -0,4592 n.s. 
Xanthine 0,0317 0,2150 n.s. 0,0317 0,7492 * 0,2150 0,7492 n.s. 
Cholesterol -0,0165 -0,2613 ** -0,0165 -0,1298 n.s. -0,2613 -0,1298 n.s. 
CA 0,0898 1,6490 n.s. 0,0898 2,0230 * 1,6490 2,0230 n.s. 
LCA -0,1801 1,2230 n.s. -0,1801 0,5337 n.s. 1,2230 0,5337 n.s. 
DCA 0,0340 2,5920 *** 0,0340 1,7480 * 2,5920 1,7480 n.s. 
G-CA -0,0016 0,2709 n.s. -0,0016 0,0892 n.s. 0,2709 0,0892 n.s. 
G-DCA 0,0326 2,0660 ** 0,0326 1,7110 n.s. 2,0660 1,7110 n.s. 
T-CA 0,0415 -0,3467 n.s. 0,0415 -0,5246 n.s. -0,3467 -0,5246 n.s. 
T-DCA 0,0710 1,1230 n.s. 0,0710 -0,1293 n.s. 1,1230 -0,1293 n.s. 
Abbreviations: CA, cholic acid; DCA, deoxycholic acid; G, glycine; LCA, lithocholic acid; PD, Parkinson’s disease; T, taurine. 
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operating in positive mode. Front inlet temperature was 
250°C, injection was performed in splitless mode. 
Transfer line and ion-source temperature were 250°C 
and 230°C, respectively. Septum purge flow was fixed 
at 3 mL/min, purge flow to split vent operated at 80 
mL/min during 1 min and gas saver mode was set to 15 
mL/min after 5 min. Helium gas flowed through column 
(J&WScientificHP-5MS, 30m x 0.25 mm, i.d. 0.25 mm, 
d.f., Agilent Technologies Inc.) at 1 mL/min. Column 
temperature was held at 60°C for 1 min, then raised to 
210°C (10°C/min), followed by a step to 230°C 
(5°C/min) and reached 325°C (15°C/min), and be hold 
at this temperature for 5 min. 
 
Collision gas was nitrogen. Scan mode used was MRM 
for biological samples. Peak detection and integration of 
analytes were performed using Agilent Mass Hunter 
quantitative software (B.07.01). 
 
Untargeted analysis of metabolites by ultra-high 
performance liquid chromatography (UHPLC) 
coupled to a Q-Exactive mass spectrometer. 
Reversed phase acetonitrile method 
 
The profiling experiment was performed with a Dionex 
Ultimate 3000 UHPLC system (Thermo Scientific) 
coupled to a Q-Exactive (Thermo Scientific) equipped 
with an electrospray source operating in both positive 
and negative mode and full scan mode from 100 to 1200 
m/z. The Q-Exactive parameters were: sheath gas flow 
rate 55 au, auxiliary gas flow rate 15 au, spray voltage 
3.3 kV, capillary temperature 300°C, S-Lens RF level 55 
V. The mass spectrometer was calibrated with sodium 
acetate solution dedicated to low mass calibration. 
 
10 μL of sample were injected on a SB-Aq column (100 
mm × 2.1 mm particle size 1.8 μm) from Agilent 
Technologies, protected by a guard column XDB-C18 
(5 mm × 2.1 mm particle size 1.8 μm) and heated at 
40°C by a Pelletier oven. The gradient mobile phase 
consists of water with 0.2% of acetic acid (A) and 
acetonitrile (B). The flow rate was set to 0.3 mL/min. 
Initial condition is 98% phase A and 2% phase B. 
Molecules were then eluted using a gradient from 2% to 
95% phase B in 22 min. The column was washed using 
95% mobile phase B for 2 minutes and equilibrated 
using 2% mobile phase B for 4 min. 
 
The autosampler was kept at 4°C. Peak detection and 
integration were performed using the Thermo Xcalibur 
quantitative software (3.1.). 
 
Quantification and statistical analysis 
 
Data are reported as Box and whisker plots (mean, first 
and third quartiles, and maximum and minimum 
values) or mean ± standard error of the mean  
(SEM). The number of independent data points (n) is 
indicated in the corresponding figure or in the 
Supplementary Tables 1 and 2. It’s important to note 
that not all metabolites are detected properly in all 
plasma samples. For this reason, the number of 
patients shown for each metabolite may suffer slight 
and punctual variations. For statistical analyses, p 
values were calculated by one-way ANOVA test 
(analyzing the metabolites individually) (Figures 2–
5), multiple tests with false discovery rate (FDR) 
(analyzing the metabolites as a whole, being part of a 
specific metabolic pathway) (Supplementary Figures 
2 and 3) and Pearson’s correlation coefficients with 
their 95% confidence interval was also used 
(Pearson’s correlation coefficient (R) (Figure 1 and 
Supplementary Figure 1) and their p-value are 
shown). Clusterings and heatmaps have been 
performed using ‘‘dist’’ and ‘‘hclust’’ functions, 
using Euclidean distance method. (Prism version 7, 
GraphPad Software). Differences were considered 
statistically significant when p-values: * (p<0.05), ** 
(p<0.01), *** (p<0.001), and n.s. = not significant 
(p>0.05). 
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Supplementary Figure 1. Pearson’s correlations in plasma samples between changes metabolite correlations (Log2FC) in idiopathic and 
p.G2019S PD patients (A) or idiopathic and p.R1441G PD patients (B). The correlation analysis divided by subtypes of metabolites (lipids, 
purines, bile acids, carbohydrates, organic acids, fatty acyls, amino acids and nucleosides) is shown by color codes (p values and Pearson’s 
coefficients of correlation (R)) (C).  
  
 
www.aging-us.com 16706 AGING 
 
 
Supplementary Figure 2. Scheme of the pathways of bile synthesis from cholesterol (A). Box and whisker plots of fold change (Log2) 
concentrations of bile acid pathway metabolites (cholesterol, CA, DCA, LCA, G-conjugated bile acids and T-conjugated bile acids) in human 
plasma in the control group (healthy) and PD individuals (B) and PD-mouse model (C). Abbreviations: 6-OHDA, 6-hydroxydopamine; CA, cholic 
acid; DCA, deoxycholic acid; G, glycine; LCA, lithocholic acid; PD, Parkinson’s disease; T, taurine; Unt, untreated. Differences were considered 
statistically significant when p-values: * (p<0.05), ** (p<0.01), *** (p<0.001). 
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Supplementary Figure 3. Scheme of the purine metabolism pathways (A). Box and whisker plots of fold change (Log2) concentrations of 
purine acids pathway metabolites (uric acid, hypoxanthine, xanthine, inosine, adenosine, guanine, guanosine and hypoxanthine/uric acid 
ratio) in human plasma from the control group (healthy) and PD individuals (B) and our PD-mouse model (C). Abbreviations: 6-OHDA, 6-
hydroxydopamine; PD, Parkinson’s disease; Unt, untreated. Differences were considered statistically significant when p-values: *** 
(p<0.001).  
 




Please browse Full Text version to see the data of Supplementary Tables 1 and 2. 
 
Supplementary Table 1. Metabolite changes in plasma from controls and PD patients.  
Supplementary Table 2. Metabolite changes in plasma from 6-OHDA mouse model. 
 
 
 
 
 
 
